State Street’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,869,876
| Closed | -$61.5M | – | 4203 |
|
|
2026
Q1 | $61.5M | Sell |
2,869,876
-1,419,690
| -33% | -$20M | ﹤0.01% | 1633 |
|
|
2025
Q4 | $40M | Buy |
4,289,566
+1,049,122
| +32% | +$8.76M | ﹤0.01% | 1864 |
|
|
2025
Q3 | $22.8M | Buy |
3,240,444
+550,758
| +20% | +$3.79M | ﹤0.01% | 2160 |
|
|
2025
Q2 | $17.5M | Sell |
2,689,686
-17,013
| -0.6% | -$117K | ﹤0.01% | 2263 |
|
|
2025
Q1 | $21.5M | Sell |
2,706,699
-394,978
| -13% | -$4.25M | ﹤0.01% | 2105 |
|
|
2024
Q4 | $39.3M | Buy |
3,101,677
+277,860
| +10% | +$3.87M | ﹤0.01% | 1845 |
|
|
2024
Q3 | $39.3M | Sell |
2,823,817
-3,003
| -0.1% | -$42.8K | ﹤0.01% | 1824 |
|
|
2024
Q2 | $39M | Sell |
2,826,820
-68,063
| -2% | -$996K | ﹤0.01% | 1790 |
|
|
2024
Q1 | $47.8M | Sell |
2,894,883
-485,215
| -14% | -$7.26M | ﹤0.01% | 1749 |
|
|
2023
Q4 | $49.3M | Buy |
3,380,098
+444,179
| +15% | +$5.38M | ﹤0.01% | 1710 |
|
|
2023
Q3 | $36M | Sell |
2,935,919
-418,407
| -12% | -$5.46M | ﹤0.01% | 1811 |
|
|
2023
Q2 | $40.1M | Buy |
3,354,326
+1,097,535
| +49% | +$14.3M | ﹤0.01% | 1804 |
|
|
2023
Q1 | $30.2M | Sell |
2,256,791
-199,744
| -8% | -$3.9M | ﹤0.01% | 1964 |
|
|
2022
Q4 | $52.9M | Buy |
2,456,535
+414,797
| +20% | +$8.51M | ﹤0.01% | 1601 |
|
|
2022
Q3 | $40.9M | Buy |
2,041,738
+1,682,955
| +469% | +$35.8M | ﹤0.01% | 1744 |
|
|
2022
Q2 | $6.42M | Buy |
358,783
+142,567
| +66% | +$1.47M | ﹤0.01% | 2968 |
|
|
2022
Q1 | $2.15M | Buy |
216,216
+26,725
| +14% | +$353K | ﹤0.01% | 3540 |
|
|
2021
Q4 | $3.19M | Buy |
189,491
+65,459
| +53% | +$1.35M | ﹤0.01% | 3467 |
|
|
2021
Q3 | $2.94M | Buy |
+124,032
| New | +$2.97M | ﹤0.01% | 3500 |
|
Other funds holding DAWN
State Street's DAWN Position: Q2 2026 in Review
State Street sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 2,869,876 shares — an estimated $61.5M sold.
State Street first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $61.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- State Street reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- State Street sold 2,869,876 Day One Biopharmaceuticals shares in Q2 2026, an estimated $61.5M.
- State Street first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- State Street's Day One Biopharmaceuticals position peaked at $61.5M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.